% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • thewanderer50 thewanderer50 Apr 2, 2014 2:32 PM Flag

    Motley Fool article.........why I sold last week

    Found the article on Yahoo Financials: Is this valid or smoke? Comments please.....

    " Why Insmed Inc. Shares Sank" by Sean Williams, 3/26/14

    "Now what: Rarely do you see such a clash of positive and next news all in one clinical study, but that's exactly what we've got here. Normally a primary endpoint failure would be the end of it and the company's share price in question would sink, but this statistically significant secondary endpoint data shows promise for Arikayce -- so much so, in fact, that research firm Leerink Swaan boosted its price target on Insmed to $30 from $22. But looking at this from a pessimists perspective, even though Arikayce only had one suspected unexpected serious adverse reaction, which is consistent with the placebo group, the sheer increase in AE'scould be concerning to physicians and patients were it to ever make it to market. Arikayce also comprises Insmed entire pipeline, albeit across two other indications outside of treatment-resistant mycobacterial lung infections. Until we have some answers on where Arikayce heads next following Insmed's talks with the Food and Drug Administration, I can't think of a better recourse than to stick to the sidelines.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
20.50+1.03(+5.29%)Mar 27 4:00 PMEDT